All News

RheumNow Podcast square

RheumNow Live is Coming to Town (3.11.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
lupus,nephritis,GN

Could Anifrolumab Work in Lupus Nephritis?

Jack Cush, MD

Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit.

Read Article
Lupus,flare,malar,DermNetNZ

Increased SLE Flares with Hydroxychloroquine Reduction

Jack Cush, MD

Concerns about the long-term safety of hydroxychloroquine (HCQ) often results in dose reduction or drug discontinuation; yet a current study shows that, for those in remission, HCQ taper/discontinuation resulted in a significantly higher rate of SLE flares.

Read Article
RheumNow Podcast square

Diagnostic Delay in Axial Spondyloarthritis (2.25.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.

Read Article
SLE,malar,black

ACR Addresses Racial Disparities in Lupus Trials

ACR

The American College of Rheumatology (ACR) is launching two new initiatives to reduce racial disparities in lupus clinical trials: Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY) and new Continuing Medical Educatio

Read Article
COVID,vaccinate,injection,green

Low COVID-19 Vaccine Risks in Rheumatic Patients

Jack Cush, MD

Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine registry shows that patients with with inflammatory or noninflammatory rheumatic and musculoskeletal disease have similar adverse event rates as the general public.

Read Article
myositis.jpg

Predicting Treatment Response in Inflammatory Muscle Disorders

MedPage Today

Rheumatologists looking for clues to whether their patients with certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study appearing in Arthritis Care & Research.

Read Article
Could Anifrolumab Work in Lupus Nephritis? Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit. https://t.co/6EtLf1nhv6 https://t.co/RrJX08vcIK

Links:

Dr. John Cush RheumNow ( View Tweet)
New Download Available! Autoimmune Disease in the USA https://t.co/KvsgBUY7mL https://t.co/PSTF7ma6G6

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Increased SLE Flares with HCQ Reduction Concerns about the long-term safety of HCQ often results in dose reduction or drug discontinuation; study shows that, for those in remission, HCQ taper/discontinuation resulted in a higher rate of SLE flares. https://t.co/l0Xh1oQzQA https://t.co/HyDbqKrEFp

Links:

Dr. John Cush RheumNow ( View Tweet)
2/28, was “Rare Disease Day” in the USA, w/many tributes to the patients, doctors & researchers dedicated to these disorders. Moreover, it was a great opportunity to shout about the many rare conditions that don’t get enough press, praise or funding. https://t.co/ft8Y8Mmdnz https://t.co/WqhRGzNRtS

Links:

Dr. John Cush RheumNow ( View Tweet)
Listen in… Fellow Case Presentations From RWCS 2022 https://t.co/SvaGfyDDTK https://t.co/MP9iWQK8ZB

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: 144 SLE pts from the SLICC cohort were studied showing that a majority (61.2%) scores consistent with depression over 4 yrs; also an inconsistent association between disease activity and depression in multivariate analysis https://t.co/YqxPFtYohf

Links:

Dr. John Cush RheumNow ( View Tweet)

SLE mortality rates (ASMR) nearly doubled since 1998 & remain high (vs non-SLE mortality) w/ significant sex & regional disparities. Data from 11449 SLE deaths, ASMR signif increased 1998 to 2009, down 2009 to 2013 and increased thereafter https://t.co/kSc3Cn2Bl5

Links:

Dr. John Cush RheumNow ( View Tweet)

144 SLE pts from the SLICC cohort were studied showing that a majority (61.2%) scores consistent with depression over 4 yrs; also an inconsistent association between disease activity and depression in multivariate analysis https://t.co/Js5jB6hlox

Links:

Dr. John Cush RheumNow ( View Tweet)

CSF aptamer (short nucleic acid sequences) discovery of neuropsychiatric lupus pts finds increase in few CSF proteins that are discriminatory -- CSF Lipocalin-2, M-CSF, IgM and complement C3, the latter assoc w/ acute confusional state. https://t.co/Mvp2U8DMh8

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult with moderate to severe, active, autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy.https://t.co/29HupHHOW6

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Challenges in Lupus: -Mortality greatest in 1st yr -Dx Delays 6.4 yrs -Long-term complications increased 50 fold -Steroids worsen long-term outcomes -Health care costs increased 3 to 5 years prior to Dx -Mean delay in drug starts after Dx =177 days https://t.co/ZMHTXBn4vm https://t.co/SX0fSxHoES

Links:

Dr. John Cush RheumNow ( View Tweet)
Predicting Treatment Response in Inflammatory Muscle Disorders Rheums looking for clues to whether their patients w/certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study in Arthritis Care & Research. https://t.co/kXFIEMTbkb https://t.co/UbO7nSsdAY

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 25/306 SLE patients (8.2%) who developed 29 episodes of Pulmonary Hemorrhage (PH). 1st manifestation . PH assoc w/ Renal dz, high SLE activity during PH; PH mortality w/ Renal failure & mech ventilation. https://t.co/ydJkgf5BFB

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×